Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
$1.17
-10.0%
$1.51
$0.19
$2.65
$20.60M3.081.39 million shs126,426 shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$1.03
+71.8%
$0.62
$0.44
$1.25
$6.00M0.41.18 million shs162.61 million shs
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
$7.37
$1.60
$6.28
$1.08M0.84180,228 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
-3.70%+8.33%-23.08%-12.16%+463.99%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-3.68%+2.60%-9.50%+7.12%+3.09%
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
0.387 of 5 stars
1.50.00.00.00.60.01.3
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
0.00
N/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
3.00
Buy$0.85-17.55% Downside
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/A$0.48 per shareN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$9.78M0.61N/AN/A$4.25 per share0.24
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/AN/AN/AN/A$3.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
-$13.23MN/A0.00N/AN/AN/A-75.46%-71.18%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/A
3.01
3.01
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.15
0.91
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/A
3.73
3.73

Institutional Ownership

CompanyInstitutional Ownership
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
13.36%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
10.70%

Insider Ownership

CompanyInsider Ownership
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
30.24%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
0.10%
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
117.60 million12.28 millionNot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
305.82 million4.88 millionNot Optionable
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
32.83 millionN/ANot Optionable

Recent News About These Companies

Pharmaceutical Stocks
CYCC Cyclacel Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Ltd.
AI Advances Pharmaceutical Packaging Inspection
The OHRP and SUPPORT — Another View
Working at the Smithsonian
OHR Pharmaceutical (OHRP) is now in Oversold Territory

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hillstream BioPharma stock logo

Hillstream BioPharma NASDAQ:HILS

$1.17 -0.13 (-10.00%)
As of 08/19/2025

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

NovaBay Pharmaceuticals stock logo

NovaBay Pharmaceuticals NYSE:NBY

$1.03 +0.43 (+71.82%)
As of 02:29 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

OHR Pharmaceutical stock logo

OHR Pharmaceutical NASDAQ:OHRP

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.